Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.79 |
| ▸ | HPGD | P15428 | 6/20 | 0.79 |
| ▸ | GLA | P06280 | 5/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.79 |
| ▸ | GAA | P10253 | 4/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.79 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.79 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.79 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.79 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.79 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.79 |
| ▸ | DRD1 | P21728 | 2/20 | 0.79 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.79 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.79 |
| ▸ | TP53 | P04637 | 2/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terazosin SCHEMBL6528 | 0.89 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL30684952 | 0.89 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL41546 | 0.89 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL5424458 | 0.89 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL5427410 | 0.88 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL41545 | 0.88 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL31284920 | 0.88 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL8057933 | 0.88 | KDM4E (0.98) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL5525882 | 0.88 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL41544 | 0.87 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034032-A1 | Quinoline and quinazoline compounds useful in therapy | PFIZER INC | 2004-02-19 | — | — | US | disclosed |
| US-6649620-B2 | Particularly in the treatment of benign prostatic hyperplasia. | PFIZER INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030045525-A1 | Quinoline and quinazoline compounds useful in therapy | COLLIS ALAN JOHN (GB) | 2003-03-06 | — | — | US | disclosed |
| EP-0875506-B1 | Quinoline and quinazoline compounds useful in therapy | PFIZER LTD (GB) | 2003-02-26 | — | — | EP | disclosed |
| EP-0875506-A1 | Quinoline and quinazoline compounds useful in therapy | Pfizer Limited (GB) | 1998-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045525-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, LPXN, BPHL | KDM4E 3830/4885ALDH1A1 670/4885HPGD 402/4885 |
| US-20040034032-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, LPXN, SDHA | KDM4E 3783/4885ALDH1A1 728/4885HPGD 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.